[Renin-angiotensin-aldosterone system inhibition: pharmacologic rationale and evaluations of drug combinations].
First-line antihypertensive monotherapy is effective in normalizing blood pressure in approximatively 50 per cent of patients. Normalization in the remaining patients may require a combination of two or more drugs. This review considers the rationale and the evaluation of combinations with drugs interacting with the renin-angiotensin system (i.e. angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor antagonists) with other drugs. The combinations may be justified when giving an additive or synergistic action and when reducing clinical or metabolic side-effects. Recent developments concern the potential benefit of combining ACEI and angiotensin receptor antagonists.
Service de Pharmacologie Clinique, CHU Sud, Amiens, France.
M
M
Andréjak
M
M
Slama
L
L
Hary
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D012084:Renin-Angiotensin System
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics
Inhibition du système rénine-angiotensine-aldostérone: rationnel pharmacologique et évaluation des associations thérapeutiques.